Chemoinformaics analysis of 2-Ethenyl-2-methyl-5-propan-2-yloxolane
| Molecular Weight | 154.253 | nRot | 2 |
| Heavy Atom Molecular Weight | 136.109 | nRig | 6 |
| Exact Molecular Weight | 154.136 | nRing | 1 |
| Solubility: LogS | -2.825 | nHRing | 1 |
| Solubility: LogP | 2.819 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 29 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 18 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 29.5043 |
| nHD | 0 | BPOL | 19.7937 |
| QED | 0.556 |
| Synth | 3.953 |
| Natural Product Likeliness | 3.13 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0 |
| HIA | 0.004 |
| CACO-2 | -4.288 |
| MDCK | 0.0000236 |
| BBB | 0.401 |
| PPB | 0.826845 |
| VDSS | 1.755 |
| FU | 0.169593 |
| CYP1A2-inh | 0.069 |
| CYP1A2-sub | 0.693 |
| CYP2c19-inh | 0.07 |
| CYP2c19-sub | 0.941 |
| CYP2c9-inh | 0.073 |
| CYP2c9-sub | 0.253 |
| CYP2d6-inh | 0.01 |
| CYP2d6-sub | 0.666 |
| CYP3a4-inh | 0.397 |
| CYP3a4-sub | 0.59 |
| CL | 7.445 |
| T12 | 0.321 |
| hERG | 0.023 |
| Ames | 0.078 |
| ROA | 0.04 |
| SkinSen | 0.26 |
| Carcinogencity | 0.137 |
| EI | 0.964 |
| Respiratory | 0.152 |
| NR-Aromatase | 0.009 |
| Antiviral | No |
| Prediction | 0.939817 |